GB201700814D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB201700814D0
GB201700814D0 GBGB1700814.5A GB201700814A GB201700814D0 GB 201700814 D0 GB201700814 D0 GB 201700814D0 GB 201700814 A GB201700814 A GB 201700814A GB 201700814 D0 GB201700814 D0 GB 201700814D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1700814.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liverpool
Liverpool School of Tropical Medicine
Original Assignee
University of Liverpool
Liverpool School of Tropical Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Liverpool, Liverpool School of Tropical Medicine filed Critical University of Liverpool
Priority to GBGB1700814.5A priority Critical patent/GB201700814D0/en
Publication of GB201700814D0 publication Critical patent/GB201700814D0/en
Priority to JP2019559413A priority patent/JP7318889B2/ja
Priority to EP18721448.1A priority patent/EP3571204A2/en
Priority to PCT/IB2018/000216 priority patent/WO2018134685A2/en
Priority to US16/478,281 priority patent/US11518760B2/en
Priority to US17/956,435 priority patent/US20230348460A1/en
Priority to JP2023004747A priority patent/JP2023052427A/ja
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1700814.5A 2017-01-17 2017-01-17 Compounds Ceased GB201700814D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB1700814.5A GB201700814D0 (en) 2017-01-17 2017-01-17 Compounds
JP2019559413A JP7318889B2 (ja) 2017-01-17 2018-01-17 化合物
EP18721448.1A EP3571204A2 (en) 2017-01-17 2018-01-17 Compounds
PCT/IB2018/000216 WO2018134685A2 (en) 2017-01-17 2018-01-17 Compounds
US16/478,281 US11518760B2 (en) 2017-01-17 2018-01-17 Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds
US17/956,435 US20230348460A1 (en) 2017-01-17 2022-09-29 ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS
JP2023004747A JP2023052427A (ja) 2017-01-17 2023-01-16 化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1700814.5A GB201700814D0 (en) 2017-01-17 2017-01-17 Compounds

Publications (1)

Publication Number Publication Date
GB201700814D0 true GB201700814D0 (en) 2017-03-01

Family

ID=58463323

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1700814.5A Ceased GB201700814D0 (en) 2017-01-17 2017-01-17 Compounds

Country Status (5)

Country Link
US (2) US11518760B2 (enExample)
EP (1) EP3571204A2 (enExample)
JP (2) JP7318889B2 (enExample)
GB (1) GB201700814D0 (enExample)
WO (1) WO2018134685A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
US11866430B2 (en) 2018-06-27 2024-01-09 Bristol-Myers Squibb Company Naphthyridinone compounds useful as T cell activators
SG11202012972YA (en) 2018-06-27 2021-01-28 Bristol Myers Squibb Co Substituted naphthyridinone compounds useful as t cell activators
CN109627207A (zh) * 2018-12-17 2019-04-16 天津药明康德新药开发有限公司 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法
CN109651171A (zh) * 2019-01-13 2019-04-19 苏州鹏旭医药科技有限公司 依拉戈利及其钠盐的中间体及其盐的制备方法和应用
BR112021015853A2 (pt) 2019-02-13 2021-10-05 Ptc Therapeutics, Inc. Compostos de tieno[3,2-b]piridin-7-amina para o tratamento de disautonomia familiar
EP3924050A1 (en) 2019-02-13 2021-12-22 PTC Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
US20230148450A9 (en) * 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
GEP20257823B (en) 2019-05-31 2025-11-10 Chiesi Farm Spa Amino quinazoline derivatives as p2x3 inhibitors
WO2020239953A1 (en) * 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Pyridopyrimidines derivatives as p2x3 inhibitors
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
BR112022011364A2 (pt) * 2019-12-12 2022-08-23 Ptc Therapeutics Inc Compostos para tratar disautonomia familiar
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CA3162985A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted quinazolinyl compounds useful as t cell activators
MX2022007130A (es) 2019-12-23 2022-07-11 Bristol Myers Squibb Co Derivados de piperazina sustituidos utiles como activadores de celulas t.
TW202208355A (zh) * 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
WO2022058896A1 (en) * 2020-09-15 2022-03-24 Cadila Healthcare Limited Inhibitors of low molecular weight protein tyrosine phosphatase for management of metabolic disorder
CN116323623B (zh) 2020-09-18 2025-09-26 拜耳公司 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺
GB202100635D0 (en) 2021-01-18 2021-03-03 Liverpool School Tropical Medicine Compounds and methods for treating or preventing dirofilaria infection in a mammal
WO2022171018A1 (zh) * 2021-02-09 2022-08-18 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
WO2022187411A1 (en) 2021-03-02 2022-09-09 Kumquat Biosciences Inc. Heterocycles and uses thereof
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
CA3246750A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. MACROCYCLES AND HETEROCYCLES AND THEIR USES
CN115160294B (zh) * 2022-06-27 2023-09-29 中山大学 一种G9a/GLP共价抑制剂及其制备方法及应用
EP4587439A1 (en) 2022-09-16 2025-07-23 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
EP4602049A1 (en) 2022-10-13 2025-08-20 Bayer Aktiengesellschaft Sos1 inhibitors
WO2024114561A1 (zh) * 2022-11-28 2024-06-06 上海美悦生物科技发展有限公司 螺杂环取代的嘧啶类化合物及其制备方法和用途
WO2025012643A1 (en) * 2023-07-11 2025-01-16 Tay Therapeutics Limited Compounds comprising a naphthyridine or pyridopyrimidine core as ptc read-through agents
WO2025147603A1 (en) * 2024-01-05 2025-07-10 Dewpoint Therapeutics, Inc. Thienopyridine compounds and uses thereof
CN119161336B (zh) * 2024-07-24 2025-09-05 四川大学 一种作为Blimp1抑制剂的小分子化合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US6262059B1 (en) * 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
AU2879799A (en) 1998-02-26 1999-09-15 Neurogen Corporation 4-(4-piperidylmethylamino) substituted heteroaryl fused pyridines: gaba brain receptor ligands
WO2001032632A2 (en) * 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
AU2002364211A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
ES2299888T3 (es) 2003-12-16 2008-06-01 Pfizer Products Incorporated Pirid (2,3-d)pirimidin-2,4-diaminas como inhibidores de pde 2.
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
CA2691932A1 (en) 2007-06-27 2008-12-31 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
WO2010042489A2 (en) * 2008-10-06 2010-04-15 Emory University Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
PH12012500097A1 (en) 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
FR2959510B1 (fr) 2010-04-28 2013-04-26 Centre Nat Rech Scient Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques
US20130345249A1 (en) * 2011-01-15 2013-12-26 The Regents Of The University Of California Formulations for the prevention and treatment of Wolbachia-related disease
CN103087077B (zh) 2011-11-03 2016-05-18 上海希迈医药科技有限公司 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
CN103204816B (zh) 2012-01-16 2016-04-27 中国人民解放军军事医学科学院毒物药物研究所 哌嗪基嘧啶类衍生物及其制备方法和用途
SI3321265T1 (sl) 2015-03-04 2020-07-31 Gilead Sciences, Inc. Spojine 4,6-diamino-pirido(3,2-d)pirimidina in njihova uporaba kot modulatorji toličnih receptorjev
CN106083742A (zh) 2016-05-31 2016-11-09 广东工业大学 一种2,4‑二胺基喹唑啉衍生物及其制备方法和应用
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds

Also Published As

Publication number Publication date
US20230348460A1 (en) 2023-11-02
WO2018134685A2 (en) 2018-07-26
WO2018134685A3 (en) 2018-11-15
US20190345157A1 (en) 2019-11-14
JP2020505454A (ja) 2020-02-20
JP2023052427A (ja) 2023-04-11
US11518760B2 (en) 2022-12-06
EP3571204A2 (en) 2019-11-27
JP7318889B2 (ja) 2023-08-01

Similar Documents

Publication Publication Date Title
GB201708456D0 (en) Senolytic compounds
GB201700814D0 (en) Compounds
GB201704327D0 (en) Compounds
GB201715342D0 (en) Compounds
GB201704325D0 (en) Compounds
GB201716871D0 (en) Compounds
GB201713962D0 (en) Compounds
GB201717051D0 (en) Compounds
GB201707938D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201706162D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201715786D0 (en) Compounds
GB201720064D0 (en) Compounds
GB201716392D0 (en) Compounds
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201721331D0 (en) Compounds
GB201721326D0 (en) Compounds
GB201721330D0 (en) Compounds
GB201720495D0 (en) ß-lactone compounds
GB201719261D0 (en) Compounds
GB201717718D0 (en) Compounds
GB201717050D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)